Cargando…

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity with clinical manifestations including infections, lymphoproliferation, autoimmunity, enteropathy, bronchiectasis, increased risk of lymphoma, and early mortality. Hyperactive PI3Kδ signaling causes APDS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, V. Koneti, Webster, Sharon, Šedivá, Anna, Plebani, Alessandro, Schuetz, Catharina, Shcherbina, Anna, Conlon, Niall, Coulter, Tanya, Dalm, Virgil A., Trizzino, Antonino, Zharankova, Yulia, Kulm, Elaine, Körholz, Julia, Lougaris, Vassilios, Rodina, Yulia, Radford, Kath, Bradt, Jason, Kucher, Klaus, Relan, Anurag, Holland, Steven M., Lenardo, Michael J., Uzel, Gulbu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Plenary Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163280/ https://www.ncbi.nlm.nih.gov/pubmed/36399712 http://dx.doi.org/10.1182/blood.2022018546

Ejemplares similares

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity
por: Preite, Silvia, et al.
Publicado: (2018)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

Activated PI3Kδ breaches multiple B cell tolerance checkpoints and causes autoantibody production
por: Lau, Anthony, et al.
Publicado: (2019)

PI3Kδ过度活化综合征一例
Publicado: (2021)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2
por: Nguyen, Tina, et al.
Publicado: (2023)

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma
por: Katsuya, Hiroo, et al.
Publicado: (2018)

PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
por: Putz, Eva Maria, et al.
Publicado: (2012)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment
por: Vanselow, Sven, et al.
Publicado: (2023)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
por: Lauder, Sarah N., et al.
Publicado: (2021)

PI3Kδ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8(+) T cells at the expense of central memory
por: Cannons, Jennifer L., et al.
Publicado: (2021)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
por: Pongas, Georgios N., et al.
Publicado: (2017)

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
por: Piddock, R E, et al.
Publicado: (2017)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Targeting PI3Kδ: One man’s meat is another man’s poison
por: Prchal-Murphy, Michaela, et al.
Publicado: (2013)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

Epidermodysplasia verruciformis in a young adult with activated PI3Kδ syndrome
por: Donaldson, Stephanie L., et al.
Publicado: (2019)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
por: Wang, Xiang, et al.
Publicado: (2014)

Phosphatidylinositol 3-Kinase (PI3K) δ blockade increases genomic instability in B cells
por: Compagno, Mara, et al.
Publicado: (2017)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection
por: Pillinger, Genevra, et al.
Publicado: (2016)

Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model
por: Serra, Ines, et al.
Publicado: (2021)

Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
por: Patton, Daniel T., et al.
Publicado: (2011)

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
por: Kim, Joo Hyun, et al.
Publicado: (2018)

Epstein–Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency
por: Carpier, Jean-Marie, et al.
Publicado: (2018)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor
por: Cai, Yu, et al.
Publicado: (2020)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_e5doe72tgjdch5kaejdcg0jec5